hematopoietic stem cells

[Cytovia Therapeutics, Inc. (GlobeNewswire, Inc.)] Cytovia Therapeutics, Inc. and Cellectis announced that they have expanded their collaboration of TALEN® gene-edited iPSC-derived natural killer (NK) and chimeric antigen receptor (CAR)-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics.

[Cancer Discovery] Scientists generated ex vivo drug response and multi-omics profiling data for a prospective series of 252 samples from 186 acute myeloid leukemia patients. Functional precision medicine tumor board integrated clinical, molecular and functional data for application in clinical treatment decisions.

[Cell Reports] Investigators showed that AT-rich interaction domain 4B (ARID4B) interfered with KITLG/KIT signaling, consequently allowing HSC differentiation. Conditional Arid4b knockout in mouse hematopoietic cells blocked fetal HSC differentiation, preventing hematopoiesis.

[Stem Cell Reports] Using Ixodes ovatus Ehrlichia, a tick-borne pathogen that causes severe shock-like illness and bone marrow aplasia, type I and II interferons promoted the loss of hematopoietic stem progenitor cells via increased cell death and enforced quiescence.

[British Journal of Cancer] The authors present a few actionable steps for basic, translational and clinical research communities in advancing the utility of the platelet transcriptome as a highly sensitive biomarker in cancer and collectively enable efforts toward clinical translation and patient benefit.

[Graphite Bio, Inc.] Graphite Bio, Inc. announced that the first patient has been enrolled in the company’s Phase I/II clinical trial of GPH101, an investigational gene-edited autologous hematopoietic stem cell therapy designed to directly correct the genetic mutation that causes sickle cell disease.